1. Home
  2. BDTX vs SBI Comparison

BDTX vs SBI Comparison

Compare BDTX & SBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

N/A

Current Price

$1.38

Market Cap

104.0M

Sector

Health Care

ML Signal

N/A

Logo Western Asset Intermediate Muni Fund Inc

SBI

Western Asset Intermediate Muni Fund Inc

N/A

Current Price

$7.01

Market Cap

100.0M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
BDTX
SBI
Founded
2014
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
104.0M
100.0M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
BDTX
SBI
Price
$1.38
$7.01
Analyst Decision
Buy
Analyst Count
8
0
Target Price
★ $11.00
N/A
AVG Volume (30 Days)
★ 766.3K
62.3K
Earning Date
11-10-2026
01-01-0001
Dividend Yield
N/A
★ 4.52%
EPS Growth
★ 130.71
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.39
$6.86
52 Week High
$3.97
$8.01

Technical Indicators

Market Signals
Indicator
BDTX
SBI
Relative Strength Index (RSI) 34.73 34.65
Support Level N/A $6.87
Resistance Level $1.94 $7.90
Average True Range (ATR) 0.14 0.06
MACD -0.04 -0.03
Stochastic Oscillator 0.84 1.39

Price Performance

Historical Comparison
BDTX
SBI

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager.

Share on Social Networks: